SK Biopharmaceuticals Co Ltd
KRX:326030
SK Biopharmaceuticals Co Ltd
KRX:326030
Price:
103 200
KRW
-1.05%
Market Cap:
8.1T
KRW
Balance Sheet
Balance Sheet Decomposition
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
| Current Assets | 651.4B |
| Cash & Short-Term Investments | 324.5B |
| Receivables | 182.4B |
| Other Current Assets | 144.4B |
| Non-Current Assets | 385.4B |
| Long-Term Investments | 91.4B |
| PP&E | 43.9B |
| Intangibles | 32.5B |
| Other Non-Current Assets | 217.5B |
Balance Sheet
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Currency: KRW
Millions
Annual
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
25 272
|
74 292
|
51 141
|
59 333
|
225 922
|
104 060
|
239 700
|
322 807
|
|
| Cash Equivalents |
25 272
|
74 292
|
51 141
|
59 333
|
225 922
|
104 060
|
239 700
|
322 807
|
|
| Short-Term Investments |
39 079
|
2 236
|
31 234
|
328 657
|
108 417
|
201 394
|
1 418
|
1 682
|
|
| Total Receivables |
15 388
|
1 531
|
2 546
|
12 638
|
61 675
|
67 021
|
115 847
|
182 436
|
|
| Accounts Receivables |
14 612
|
118
|
1 379
|
9 992
|
56 460
|
66 326
|
111 422
|
173 909
|
|
| Other Receivables |
776
|
1 413
|
1 167
|
2 646
|
5 214
|
694
|
4 425
|
8 526
|
|
| Inventory |
865
|
162
|
6 733
|
23 040
|
51 933
|
90 920
|
102 525
|
111 679
|
|
| Other Current Assets |
1 225
|
3 336
|
7 027
|
10 935
|
23 272
|
24 530
|
29 232
|
32 768
|
|
| Total Current Assets |
81 828
|
81 558
|
98 681
|
434 603
|
471 219
|
487 925
|
488 722
|
651 371
|
|
| PP&E Net |
13 822
|
12 154
|
25 897
|
24 233
|
22 938
|
20 350
|
47 753
|
43 932
|
|
| PP&E Gross |
0
|
12 154
|
25 897
|
24 233
|
22 938
|
20 350
|
47 753
|
43 932
|
|
| Accumulated Depreciation |
0
|
19 691
|
22 825
|
30 356
|
37 056
|
45 101
|
54 599
|
67 577
|
|
| Intangible Assets |
246
|
246
|
883
|
19 695
|
18 900
|
17 181
|
23 633
|
30 838
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
3 392
|
1 691
|
|
| Note Receivable |
36
|
41
|
41
|
0
|
27
|
79
|
85
|
80
|
|
| Long-Term Investments |
459
|
7
|
7
|
6 849
|
107 665
|
99 959
|
104 091
|
91 439
|
|
| Other Long-Term Assets |
1 976
|
1 530
|
13 564
|
14 862
|
22 904
|
38 748
|
55 494
|
217 459
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
3 392
|
1 691
|
|
| Total Assets |
98 367
N/A
|
95 536
-3%
|
139 073
+46%
|
500 241
+260%
|
643 652
+29%
|
664 241
+3%
|
723 171
+9%
|
1 036 811
+43%
|
|
| Liabilities | |||||||||
| Accounts Payable |
23 828
|
0
|
0
|
8 954
|
16 931
|
23 106
|
2 346
|
3 403
|
|
| Accrued Liabilities |
16 273
|
24 034
|
35 103
|
36 543
|
64 776
|
55 035
|
71 331
|
79 653
|
|
| Short-Term Debt |
0
|
0
|
100 000
|
0
|
0
|
0
|
50 000
|
50 000
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
3 197
|
4 906
|
5 481
|
5 644
|
7 061
|
107 806
|
|
| Other Current Liabilities |
6 878
|
6 936
|
7 341
|
20 193
|
61 117
|
79 287
|
110 881
|
155 414
|
|
| Total Current Liabilities |
46 978
|
30 970
|
145 641
|
70 595
|
148 306
|
163 073
|
241 619
|
396 276
|
|
| Long-Term Debt |
0
|
0
|
5 858
|
13 572
|
10 256
|
150 252
|
120 989
|
26 676
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1 909
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
37 265
|
27 711
|
|
| Other Liabilities |
4 146
|
5 936
|
599
|
37 007
|
40 903
|
34 356
|
37 703
|
39 874
|
|
| Total Liabilities |
51 125
N/A
|
36 906
-28%
|
152 098
+312%
|
121 175
-20%
|
199 465
+65%
|
347 681
+74%
|
439 484
+26%
|
490 538
+12%
|
|
| Equity | |||||||||
| Common Stock |
25 000
|
32 500
|
32 500
|
39 157
|
39 157
|
39 157
|
39 157
|
39 157
|
|
| Retained Earnings |
286 862
|
426 403
|
498 948
|
746 951
|
689 141
|
827 555
|
861 561
|
621 532
|
|
| Additional Paid In Capital |
303 579
|
446 040
|
446 040
|
1 084 848
|
1 084 848
|
1 084 848
|
1 084 848
|
1 084 848
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
268
|
11 816
|
13 242
|
28 122
|
|
| Other Equity |
5 525
|
6 493
|
7 383
|
2 013
|
9 056
|
8 296
|
8 001
|
15 678
|
|
| Total Equity |
47 243
N/A
|
58 629
+24%
|
13 025
N/A
|
379 067
N/A
|
444 187
+17%
|
316 560
-29%
|
283 686
-10%
|
546 273
+93%
|
|
| Total Liabilities & Equity |
98 367
N/A
|
95 536
-3%
|
139 073
+46%
|
500 241
+260%
|
643 652
+29%
|
664 241
+3%
|
723 171
+9%
|
1 036 811
+43%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
50
|
65
|
65
|
78
|
78
|
78
|
78
|
78
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
